Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 3/20 | 0.39 |
| ▸ | MMP2 | P08253 | 2/20 | 0.39 |
| ▸ | MMP3 | P08254 | 2/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | REN | P00797 | 1/20 | 0.32 |
| ▸ | CTSD | P07339 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.31 |
| ▸ | PER2 | O15055 | 1/20 | 0.31 |
| ▸ | CRY1 | Q16526 | 1/20 | 0.31 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.30 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7157709 | 1.00 | MMP13 (0.39) | MMP13MMP2MMP3MMP9REN | |
| SCHEMBL7118822 | 0.86 | MMP2 (0.39) | MMP13MMP2RENCTSDBACE1 | |
| SCHEMBL7118832 | 0.86 | MMP2 (0.39) | MMP13MMP2RENCTSDBACE1 | |
| SCHEMBL7123582 | 0.86 | MMP2 (0.39) | MMP13MMP2RENCTSDBACE1 | |
| SCHEMBL7128682 | 0.84 | MMP2 (0.40) | MMP13MMP2MEN1KMT2A | |
| SCHEMBL7128688 | 0.84 | MMP2 (0.40) | MMP13MMP2MEN1KMT2A | |
| SCHEMBL7156503 | 0.83 | MMP13 (0.45) | MMP13MMP2MMP3MMP9PER2 | |
| SCHEMBL7156500 | 0.83 | MMP13 (0.45) | MMP13MMP2MMP3MMP9PER2 | |
| SCHEMBL7156507 | 0.83 | MMP13 (0.45) | MMP13MMP2MMP3MMP9PER2 | |
| SCHEMBL7127883 | 0.81 | ADAMTS5 (0.40) | MMP13MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030134880-A1 | Novel cd23 inhibitors | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-07-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134880-A1 | Novel cd23 inhibitors | CD2, CD22, CD40 | MMP13 335/4885MMP2 1392/4885MMP3 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.